Karen T Liby Selected Research

1- (2- cyano- 3,12- dioxooleana- 1,9- dien- 28- oyl) imidazole

12/2016	The triterpenoid CDDO-imidazolide reduces immune cell infiltration and cytokine secretion in the KrasG12D;Pdx1-Cre (KC) mouse model of pancreatic cancer.
10/2015	Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention.
7/2015	Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.
12/2014	The synthetic triterpenoid (CDDO-Im) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis in mice.
1/2014	A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer.
9/2013	Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression.
3/2011	CDDO-imidazolide induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells.
3/2011	The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis.
11/2009	The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice.
10/2009	Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karen T Liby Research Topics

Disease

41	Neoplasms (Cancer) 01/2022 - 09/2004
15	Inflammation (Inflammations) 12/2020 - 02/2006
14	Breast Neoplasms (Breast Cancer) 01/2022 - 09/2004
13	Carcinogenesis 10/2021 - 02/2006
7	Lung Neoplasms (Lung Cancer) 10/2021 - 01/2014
6	Pancreatic Neoplasms (Pancreatic Cancer) 12/2020 - 03/2010
4	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2022 - 01/2019
4	Neoplasm Metastasis (Metastasis) 10/2018 - 03/2011
4	Body Weight (Weight, Body) 11/2009 - 02/2006
3	Carcinoma (Carcinomatosis) 10/2015 - 03/2010
3	Chronic Disease (Chronic Diseases) 01/2014 - 01/2012
2	Melanoma (Melanoma, Malignant) 01/2022 - 03/2011
2	Pancreatitis 12/2020 - 12/2018
2	Obesity 01/2019 - 10/2009
2	Triple Negative Breast Neoplasms 01/2019 - 01/2014
2	Parkinson Disease (Parkinson's Disease) 01/2013 - 06/2009
2	Neuroinflammatory Diseases 07/2011 - 01/2011
1	Hyperplasia 01/2021
1	Hypertriglyceridemia 12/2020
1	Alopecia (Baldness) 01/2019
1	Hepatomegaly 01/2019
1	Cerebral Malaria 11/2017
1	Malaria 11/2017
1	Weight Loss (Weight Reduction) 01/2017
1	Leukemia 10/2015

Drug/Important Bio-Agent (IBA)

27	TriterpenesIBA 01/2022 - 02/2006
17	bardoxoloneIBA 11/2017 - 09/2004
15	1- (2- cyano- 3,12- dioxooleana- 1,9- dien- 28- oyl) imidazoleIBA 12/2016 - 09/2004
11	bardoxolone methylIBA 01/2022 - 09/2004
8	oleananeIBA 11/2017 - 05/2007
6	Bexarotene (LGD1069)FDA Link 01/2022 - 01/2019
6	AcidsIBA 01/2022 - 09/2004
6	Pharmaceutical PreparationsIBA 12/2020 - 07/2015
6	Proteins (Proteins, Gene)FDA Link 01/2018 - 11/2009
5	EnzymesIBA 12/2018 - 01/2007
5	imidazoleIBA 03/2011 - 02/2006
4	Retinoid X Receptors (Retinoid X Receptor)IBA 01/2022 - 01/2019
4	vinyl carbamateIBA 10/2021 - 10/2015
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 07/2014
4	LG 100268IBA 01/2019 - 11/2010
4	CytokinesIBA 12/2018 - 01/2011
3	EstersIBA 01/2022 - 03/2010
3	talazoparibIBA 01/2021 - 01/2017
3	CarcinogensIBA 01/2019 - 10/2015
2	LigandsIBA 01/2022 - 01/2019
2	AntibodiesIBA 10/2021 - 01/2019
2	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2019
2	Estrogen ReceptorsIBA 01/2020 - 01/2013
2	LG 268IBA 01/2019 - 11/2010
2	Phosphotransferases (Kinase)IBA 10/2018 - 09/2013
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2018 - 01/2017
2	Cyclin D1IBA 10/2018 - 01/2012
2	2- cyano- 3,12- dioxooleana- 1,9(11)- dien- 28- oic acid ethyl amideIBA 11/2017 - 11/2010
2	Histone Deacetylase InhibitorsIBA 01/2016 - 01/2013
2	Vorinostat FDA Link 01/2016 - 01/2013
2	Carboplatin (JM8)FDA LinkGeneric 01/2016 - 01/2014
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2016 - 01/2014
2	Interleukin-17 (Interleukin 17)IBA 12/2014 - 01/2011
2	Messenger RNA (mRNA)IBA 01/2013 - 01/2011
2	Transcription Factors (Transcription Factor)IBA 01/2012 - 11/2009
2	Neuroprotective AgentsIBA 07/2011 - 06/2009
2	(2- cyano- 3,12- dioxooleana- 1,9- dien- 28- oic acid) trifluoroethylamideIBA 07/2011 - 01/2011
2	NF-E2-Related Factor 2IBA 07/2011 - 06/2009
2	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2011 - 08/2006
2	AntioxidantsIBA 01/2011 - 11/2009
2	Oleanolic AcidIBA 01/2011 - 02/2006
2	Gemcitabine FDA Link 11/2010 - 03/2010
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2021
1	AgarIBA 01/2021
1	Estrogens (Estrogen)FDA Link 01/2021
1	INCB057643IBA 12/2020
1	Triglycerides (Triacylglycerol)IBA 01/2019
1	Liposomes (Liposome)IBA 01/2019
1	CholesterolIBA 01/2019
1	OligopeptidesIBA 12/2018
1	AntigensIBA 12/2018
1	CeruletideIBA 12/2018
1	Protein Isoforms (Isoforms)IBA 10/2018
1	OximesIBA 10/2018
1	Antimalarials (Antimalarial Agents)IBA 11/2017
1	Immunomodulating AgentsIBA 11/2017
1	ArtesunateIBA 11/2017
1	DNA (Deoxyribonucleic Acid)IBA 01/2017
1	Interleukin-6 (Interleukin 6)IBA 01/2017
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2017
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2017
1	7- (2- (2,2- difluoroethoxy)- 3,5- di- tert- butylbenzene)- 3- methylocta- 2,4,6- trienoic acidIBA 01/2016
1	Dimethyl FumarateIBA 07/2015
1	Trastuzumab (Herceptin)FDA Link 01/2015
1	Lapatinib (GW572016)FDA Link 01/2015
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2015
1	Dextran SulfateIBA 12/2014
1	Sulfonic AcidsIBA 12/2014

Therapy/Procedure

9	Chemoprevention 03/2021 - 10/2005
6	Therapeutics 01/2021 - 07/2015
4	Oral Administration 09/2013 - 11/2009
3	Immunotherapy 01/2022 - 03/2010
2	Immunomodulation 01/2021 - 01/2019
1	Drug Therapy (Chemotherapy) 01/2021
1	Radical Mastectomy 01/2021